Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use.
Therapeutic advances in urology. 2018 Sep 26*** epublish ***
Sara J Allison, William Gibson
Division of Geriatric and Stroke Medicine, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK., Division of Geriatric Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83Ave, Edmonton, Alberta, T6G 2P4, Canada.